Chronic Critical Limb Ischemia

Dohmen, A; Eder, Stephan; Euringer, Wulf; Zeller, Thomas; Beyersdorf, Friedhelm

doi:10.3238/arztebl.2012.0095

Cited by 22 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 In another study, it has been indicated that postoperative wound healing is problematic in 15 to 25% of patients, the rate of bypass infections is 1 to 3% (especially higher in prosthetic grafts), and the rates of early perioperative and 1-year mortality are 1 to 2% and 10%, respectively. 39 Venous arterialization can be considered as last resort for limb salvage in CLI patients with no revascularization options. It is a unique surgical procedure in which the venous bed is used as an alternative conduit for perfusion of peripheral tissues.…”

Section: Surgical Revascularizationmentioning

confidence: 99%

Current Status of Arterial Revascularization for the Treatment of Critical Limb Ischemia in Infrainguinal Atherosclerotic Disease

et al. 2018

View full text Add to dashboard Cite

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD) that may result in limb loss and even death; thus, the fast and proper treatment should be employed as earlier as possible to prevent these catastrophic consequences. Arterial revascularization is almost always an indispensable treatment option for CLI. Although both endovascular and surgical revascularization procedures have an important role, nowadays, the hybrid revascularization as a combination of these revascularization procedures has also gained increasing popularity in the treatment of patients with CLI. This review provides an update on the arterial revascularization strategies for the treatment of CLI.

show abstract

Section: Surgical Revascularizationmentioning

confidence: 99%

Current Status of Arterial Revascularization for the Treatment of Critical Limb Ischemia in Infrainguinal Atherosclerotic Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…На практике только у 37,3-58% больных выполняется адекватная реваскуляризация нижних конечностей [9]. В течение 1-го года положительный результат после операции сохраняется при реконструкциях выше щели коленного сустава в 49,1-72,3% наблюдений и при различных видах дистальных шунтирований в 10,2-39,1% случаев [10][11][12][13].…”

Section: заболевания аорты и ее ветвейunclassified

Modern possibilities to predict surgical outcomes in patients with chronic lower limb ischemia

Гавриленко¹,

Gavrilenko²,

Al-Yousef³

2017

Kardiol. serdechno-sosud. khir.

View full text Add to dashboard Cite

“…5,6 A conservative estimate of CLI patients in the United States is 250,000, of whom about one-third are poor or no-option patients. [7][8][9][10] A number of multiple gene-and cell-based therapies have been examined in PAD patients in general, and in no-option patients more specifically. 11 The application of angiogenic proteins and DNA encoding of such proteins have received considerable attention, but have failed to provide significant results.…”

Section: Introductionmentioning

confidence: 99%

Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia

et al. 2017

View full text Add to dashboard Cite

Critical limb ischemia (CLI) is the most severe presentation of peripheral arterial disease. We developed cell-based therapy entailing intra-arterial injection of autologous venous endothelial cells (ECs) modified to express angiopoietin 1, combined with autologous venous smooth muscle cells (SMCs) modified to express vascular endothelial growth factor. This combination promoted arteriogenesis in animal models and was safe in patients with limiting claudication. In an open-label, phase Ib study, we assessed the safety and efficacy of this therapy in CLI patients who failed or were unsuitable for surgery or intravascular intervention. Of 23 patients enrolled, 18 with rest pain or non-healing ulcers (Rutherford categories 4 and 5) were treated according to protocol, and 5 with significant tissue loss (Rutherford 6) were treated under compassionate treatment. Patients were assigned randomly to receive 1 × 10 or 5 × 10 (EC-to-SMC ratio, 1:1) of the cell combination. One-year amputation-free survival rate was 72% (13/18) for Rutherford 4 and 5 patients; all 5 patients with Rutherford 6 underwent amputation. Of the 12 with unhealing ulcers at dosing, 6 had complete healing and 2 others had >66% reduction in ulcer size. Outcomes did not differ between the dose groups. No severe adverse events were observed related to the therapy.

show abstract

Chronic Critical Limb Ischemia

Cited by 22 publications

References 30 publications

Current Status of Arterial Revascularization for the Treatment of Critical Limb Ischemia in Infrainguinal Atherosclerotic Disease

Current Status of Arterial Revascularization for the Treatment of Critical Limb Ischemia in Infrainguinal Atherosclerotic Disease

Modern possibilities to predict surgical outcomes in patients with chronic lower limb ischemia

Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia

Contact Info

Product

Resources

About